Terms: = Lung cancer AND TCL1A, P56279, 8115, ENSG00000100721, TCL1
14 results:
1. Aberrant activation of tcl1a promotes stem cell expansion in clonal haematopoiesis.
Weinstock JS; Gopakumar J; Burugula BB; Uddin MM; Jahn N; Belk JA; Bouzid H; Daniel B; Miao Z; Ly N; Mack TM; Luna SE; Prothro KP; Mitchell SR; Laurie CA; Broome JG; Taylor KD; Guo X; Sinner MF; von Falkenhausen AS; Kääb S; Shuldiner AR; O'Connell JR; Lewis JP; Boerwinkle E; Barnes KC; Chami N; Kenny EE; Loos RJF; Fornage M; Hou L; Lloyd-Jones DM; Redline S; Cade BE; Psaty BM; Bis JC; Brody JA; Silverman EK; Yun JH; Qiao D; Palmer ND; Freedman BI; Bowden DW; Cho MH; DeMeo DL; Vasan RS; Yanek LR; Becker LC; Kardia SLR; Peyser PA; He J; Rienstra M; Van der Harst P; Kaplan R; Heckbert SR; Smith NL; Wiggins KL; Arnett DK; Irvin MR; Tiwari H; Cutler MJ; Knight S; Muhlestein JB; Correa A; Raffield LM; Gao Y; de Andrade M; Rotter JI; Rich SS; Tracy RP; Konkle BA; Johnsen JM; Wheeler MM; Smith JG; Melander O; Nilsson PM; Custer BS; Duggirala R; Curran JE; Blangero J; McGarvey S; Williams LK; Xiao S; Yang M; Gu CC; Chen YI; Lee WJ; Marcus GM; Kane JP; Pullinger CR; Shoemaker MB; Darbar D; Roden DM; Albert C; Kooperberg C; Zhou Y; Manson JE; Desai P; Johnson AD; Mathias RA; ; Blackwell TW; Abecasis GR; Smith AV; Kang HM; Satpathy AT; Natarajan P; Kitzman JO; Whitsel EA; Reiner AP; Bick AG; Jaiswal S
Nature; 2023 Apr; 616(7958):755-763. PubMed ID: 37046083
[TBL] [Abstract] [Full Text] [Related]
2. Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy.
Zhang L; Shi Y; Han X
Front Immunol; 2022; 13():1032221. PubMed ID: 36505471
[TBL] [Abstract] [Full Text] [Related]
3. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
[TBL] [Abstract] [Full Text] [Related]
4. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Niemann CU; Mora-Jensen HI; Dadashian EL; Krantz F; Covey T; Chen SS; Chiorazzi N; Izumi R; Ulrich R; Lannutti BJ; Wiestner A; Herman SEM
Clin Cancer Res; 2017 Oct; 23(19):5814-5823. PubMed ID: 28645939
[No Abstract] [Full Text] [Related]
5. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
[No Abstract] [Full Text] [Related]
6. The effect of late-phase contrast enhancement on semi-automatic software measurements of CT attenuation and volume of part-solid nodules in lung adenocarcinomas.
Cohen JG; Goo JM; Yoo RE; Park SB; van Ginneken B; Ferretti GR; Lee CH; Park CM
Eur J Radiol; 2016 Jun; 85(6):1174-80. PubMed ID: 27161068
[TBL] [Abstract] [Full Text] [Related]
7. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer.
Pekarsky Y; Balatti V; Palamarchuk A; Rizzotto L; Veneziano D; Nigita G; Rassenti LZ; Pass HI; Kipps TJ; Liu CG; Croce CM
Proc Natl Acad Sci U S A; 2016 May; 113(18):5071-6. PubMed ID: 27071132
[TBL] [Abstract] [Full Text] [Related]
8. Mosaic loss of chromosome Y is associated with common variation near tcl1a.
Zhou W; Machiela MJ; Freedman ND; Rothman N; Malats N; Dagnall C; Caporaso N; Teras LT; Gaudet MM; Gapstur SM; Stevens VL; Jacobs KB; Sampson J; Albanes D; Weinstein S; Virtamo J; Berndt S; Hoover RN; Black A; Silverman D; Figueroa J; Garcia-Closas M; Real FX; Earl J; Marenne G; Rodriguez-Santiago B; Karagas M; Johnson A; Schwenn M; Wu X; Gu J; Ye Y; Hutchinson A; Tucker M; Perez-Jurado LA; Dean M; Yeager M; Chanock SJ
Nat Genet; 2016 May; 48(5):563-8. PubMed ID: 27064253
[TBL] [Abstract] [Full Text] [Related]
9. NANOG signaling promotes metastatic capability of immunoedited tumor cells.
Lee HJ; Noh KH; Lee YH; Song KH; Oh SJ; Kim SY; Kim TW
Clin Exp Metastasis; 2015 Jun; 32(5):429-39. PubMed ID: 25899063
[TBL] [Abstract] [Full Text] [Related]
10. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
Fiskus W; Saba N; Shen M; Ghias M; Liu J; Gupta SD; Chauhan L; Rao R; Gunewardena S; Schorno K; Austin CP; Maddocks K; Byrd J; Melnick A; Huang P; Wiestner A; Bhalla KN
Cancer Res; 2014 May; 74(9):2520-32. PubMed ID: 24599128
[TBL] [Abstract] [Full Text] [Related]
11. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
Badve S; Collins NR; Bhat-Nakshatri P; Turbin D; Leung S; Thorat M; Dunn SE; Geistlinger TR; Carroll JS; Brown M; Bose S; Teitell MA; Nakshatri H
Am J Pathol; 2010 May; 176(5):2139-49. PubMed ID: 20228224
[TBL] [Abstract] [Full Text] [Related]
12. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis.
Hu T; Liu S; Breiter DR; Wang F; Tang Y; Sun S
Cancer Res; 2008 Aug; 68(16):6533-40. PubMed ID: 18701476
[TBL] [Abstract] [Full Text] [Related]
13. T-cell prolymphocytic leukemia involving extramedullary sites.
Valbuena JR; Herling M; Admirand JH; Padula A; Jones D; Medeiros LJ
Am J Clin Pathol; 2005 Mar; 123(3):456-64. PubMed ID: 15716243
[TBL] [Abstract] [Full Text] [Related]
14. Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer.
Dillman RO; Beutel LD; De Leon C; Nayak SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):205-11. PubMed ID: 11471485
[TBL] [Abstract] [Full Text] [Related]
